There is considerable literature on renal atheroembolic disease. The early paper of Thurlbeck and Castleman [1] showed that in post-mortem renal histology analysis after aortic aneurysm repair followed by death there was an incidence of renal atheroembolic Correspondence and offprint requests to: John E. Scoble, Guy's Hospital, St Thomas Street, London SE1 9RT, UK. Email: john.scoble@gstt.sthames.nhs.uk disease of >70%. It also showed that there was a >20% incidence of atheroembolic disease in individuals with no intervention but severe aortic atherosclerotic disease. Flory [2] showed that this condition is related to cholesterol crystal embolization to the renal vascular bed and suggested that the vessels occluded were between 55 and 900 mm in diameter. There is also some recent experimental evidence by Kimura et al. [3] using acryl bead microspheres to mimic atheroembolic disease in rats. These microspheres were 20-30 mm in diameter and the histological features produced were similar to those with atheroembolic disease in humans. The spheres lodge in the small arterioles and glomeruli. They are probably a little smaller than the cholesterol clefts in vivo that may be 20 mm in diameter but have a greater length. Two important points emerged from this report. The first is that the outcomes in terms of proteinuria and renal dysfunction were dependent on the initial dose of microspheres. Only large doses induced proteinuria and only at the largest dose was there a decline in renal function. This is in keeping with the insidiously progressive form of atheroembolic disease rather than the acute catastrophic form. With low doses of microspheres there was no proteinuria or renal dysfunction. The second important point is that the maximum effect of embolization was only seen at 12 weeks. The important issue from these experimental scenarios is whether there is a dose-effect relationship in atheroembolic disease. Will reducing the dose of atheroembolic debris alter the outcome?
Embolization at angioplasty?
There is an interesting report by Rapp et al. [4] in an ex vivo preparation of carotid vessels with interventions and analysis of the effluent that has shed new light on this issue (Figure 1 ). The authors showed that the passing of an initial guide wire produced emboli but there was a significant increase with angioplasty and even more with stent placement. There has also been Doppler analysis of cerebral blood flow and microemboli generation during carotid angioplasty and carotid endarterectomy [5] . The signals recorded were interpreted to reflect debris in the carotid circulation. Of note signal registration was much greater in patients having angioplasty rather than in those undergoing surgery. Moreover, there was a relationship between Doppler recognition of emboli and neurological sequelae with a lower incidence of neurological events in the surgery rather than in the angioplasty cohort.
There are no data on renal artery Doppler recognition of emboli and intervention. However, AlHamili et al. [6] reported interesting findings in patients undergoing iliac angioplasty. These authors recorded Doppler signals over the femoral arteries after iliac angioplasty. As they needed a control group they elected to compare their findings with Doppler signals recorded over the femoral arteries in patients having renal angioplasty. Although the signals were low compared with iliac angioplasty there were embolic events recorded for 2 h after renal angioplasty in the femoral arteries. It is sobering to speculate on the Doppler signals that would be recorded over the renal artery in that situation. The data suggest that there is significant debris release in renal angioplasty and this will not surprise any nephrologist.
Embolization and type of procedure
It is well described in a number of articles that a proportion of patients will benefit from angioplasty with or without stent placement [7, 8] . At the same time all the series have shown patients who have had a decrement in renal function with this procedure. Single stent glomerular filtration rate estimations before and within 3 months of the procedure showed that a number of kidneys suffer a decline in function after angioplasty [8] .
There are three types of protection device from a number of manufacturers [9] . One developed for carotid angioplasty and stent placement involves reversal of blood flow through the carotid during the angioplasty procedure and is not applicable to the renal artery. The second type is a soft balloon inflated distal to the angioplasty/stent placement to occlude the lumen. At the end of the procedure debris is aspirated from the occluded vessel after the removal of the stent placement device. The balloon is then deflated and withdrawn. The third type of device is a filter that is deployed distal to the angioplasty site to catch any fragments that may be dislodged [10] . It is not clear whether this device will catch single cholesterol crystals. It is also clear that manoeuvring these devices into the renal artery may in itself lead to cholesterol embolization.
Studies have shown that there is considerable debris from carotid artery stenting. Angelini et al. [11] using the Angioguard device, which is a filter device, found the particle size ranged from 1.1 to 5044 mm in the major axis and 0.7 to 1175 mm in the minor axis. Debris was detected in 84% of filters. Webb et al. [12] with Fig. 1 . In vitro manipulations of carotid artery segments. GW, guide wire insertion; AP, first angioplasty; AP2, second angioplasty; AP2 þ S angioplasty plus stent insertion. Data from Rapp et al. [4] . cardiac saphenous vein graft intervention showed that particulate debris were found in 91% of cases. Particle size was 204 Â 83 mm. All these studies show that in any intervention there is release of atheroembolic material of the size shown by Flory [2] to be important.
Stent protection
There is compelling evidence from cardiac stent placement that they are effective. A study by Baim et al. [13] , with over 800 patients randomized to stent placement with or without a protective device, showed a significant difference in terms of the defined endpoints ( Figure 2 ). The device used in this study was an occlusive balloon device. There was a significant reduction in the primary endpoint from 16.5 to 9.6% when a protection device was used. The endpoint was a composite of death, myocardial infarction, emergency bypass or target vessel revascularization. These represent very short-term events and there does not appear to be a similar scenario to the progressive dysfunction seen with renal atheroembolic disease. However, this is a major validation of the use of protective devices in the coronary circulation.
There is one preliminary report of protection device in patients with renal artery stenosis [14] . This was with a PercuSurge GuardWire device that is a balloon occlusive device. The patients had excellent renal function and were undergoing intervention for hypertension control. The authors noticed no change in renal function on follow-up but found debris with all the patients of a size that would fit the vessel size affected in the Flory article [2] .
Conclusion and perspective
It is now clear from the new data that atheroemboli are the rule in any intervention in atherosclerotic disease [15] . The lack of frequency of this important clinical outcome is by luck rather than an understanding of the underlying pathophysiological processes or appropriate measures to avoid it. Angioplasty and stent placement will automatically release atheroemboli to the renal circulation. It is also clear that the effect of this cannot be overwhelming, as angioplasty/stent placement can be associated with an improvement in renal function. At the same time, the experimental evidence suggests that there is a dose effect of atheroemboli and that the result after angioplasty may depend on the dose of cholesterol crystals released to the renal circulation. It is unlikely that any device will preclude any cholesterol embolization as the experimental data show that even the guide wire placement will produce this. However, it is also possible that the heterogeneous response of the kidney to angioplasty in patients with atherosclerotic disease, compared with the beneficial response to angioplasty in fibromuscular dysplasia, may depend on the amount of cholesterol crystals released by the procedure. At present neither of the two randomized trials underway in Europe have addressed the issue of protection devices. However, it may be possible for smaller trials with single kidney function measurements to be performed to address this issue. If there were changes in outcome similar to the randomized trial in coronary artery disease then it would be difficult not to use protection devices in routine practice.
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Introduction
Acute rejection rates after renal transplantation are steadily decreasing due to more effective immunosuppressive therapies. However, more powerful prevention of immunological damage to the kidney by increasing immunosuppression is a two-edged sword, as infectious complications tend to rise in such a setting. Viral infections significantly contribute to morbidity and mortality after renal transplantation [1] , and the spectrum of some viral diseases may have changed in recent years. Rapid diagnosis, appropriate antiviral treatment and management of concurrent medications are warranted to prevent patients from potentially severe disease manifestations. This brief review will focus on current considerations concerning infections with human herpes viruses (HHV) and their treatment in renal transplant recipients.
Cytomegalovirus (HHV-5)
Cytomegalovirus (CMV) infection is the most prevalent viral infection in renal transplant recipients [2] . Depending on the individual serostatus, patients may develop either primary infection, superinfection or reactivation of CMV infection. Seropositive transplant recipients with detectable CMV-IgG-antibodies develop a symptomatic CMV infection in $10% of cases, whereas seronegative recipients transplanted from a seropositive donor (Dþ/R-) have a risk of up to 50% of developing CMV disease [1, 2] . In order to minimize the occurrence of 'tissue-invasive' CMV disease (hepatitis, enteritis, pneumonitis), virus replication should be monitored weekly by immunostaining of the pp65 antigen in peripheral blood leucocytes or by quantitative real-time-PCR techniques during the first 3-4 months after transplantation.
Dþ/R-recipients and patients with anti-lymphocyte induction or rejection therapy are recommended to receive antiviral prophylaxis. Most transplantation centres otherwise initiate preemptive antiviral treatment at the time when detection of virus replication becomes significant, but before symptoms of CMV disease occur. However, it is not clear whether this preemptive approach is indeed superior when compared with a deferred therapy, i.e. started at the time when overt CMV disease manifestations are present. There is also the unresolved question, at which threshold should preemptive therapy be initiated to prevent CMV disease? For example, are one to two pp65-positive cells per 50 000 leucocytes sufficient to justify antiviral treatment, or could reduction of immunosuppression alone be effective in suppressing CMV replication?
The recognition of CMV infection and disease seems to have changed in recent years. This may either be due to more sophisticated and more frequent testing, or to changing patterns of disease manifestations, possibly because of more effective immunosuppression. For example, CMV enteritis showing a variable clinical picture including diarrhoea, dysphagia, epigastric pain as well as upper and lower gastrointestinal bleeding is increasingly observed in transplant recipients, but
